Filing Flows › Fennec Pharmaceuticals (FENC) › Q4 2024
Fennec Pharmaceuticals (FENC) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 26, 2025
Fennec Pharmaceuticals (FENC) reported revenue of $7.9M for the fourth quarter 2024 (Q4 2024), -19% from a year earlier and +14% from the quarter before. Operating margin was -11.8%, net loss $2.0M (25.0% of revenue).
Fennec Pharmaceuticals, Q4 2024: revenue $7.9M (-19% year over year), operating margin -11.8%, net loss $2.0M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.9M | +14% | -19% |
| Operating profit | −$934K | — | — |
| Net earnings | −$2.0M | — | — |
| Operating cash flow | −$1.5M | — | — |
What changed
Revenue was $7.9M in Q4 2024, down 19% year over year and up 14% from the previous quarter.
Operating costs exceeded revenue by $934K, an operating margin of -11.8%. The fastest-growing cost line was Research & development (+56%). The quarter ended with a net loss of $2.0M, narrower than the previous quarter's $5.7M loss. Net interest and other expense of $1.1M was the main reason.
Operating cash flow was −$1.5M. Non-cash charges added back $1.1M of share-based compensation. Working capital and other items used $613K.
Questions
What was Fennec Pharmaceuticals' revenue in the fourth quarter 2024?
Fennec Pharmaceuticals (FENC) reported revenue of $7.9M for the fourth quarter 2024 (Q4 2024), -19% from a year earlier and +14% from the quarter before.
Was Fennec Pharmaceuticals profitable in the fourth quarter 2024?
Operating loss was $934K (-11.8% of revenue) and net loss $2.0M.